Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
We retrospectively studied 97 acute myeloid leukemia patients with trisomy 19 (median age at diagnosis 57 years; range, 17- 83 years) treated between 2001 and 2019 within two multicenter study groups. Trisomy 19 occurred alone in ten (10.5%) patients, with additional abnormalities being present in non-complex karyotypes in eight (8%) patients and in complex karyotypes in 79 (82%) patients. Altogether, karyotypes characterized by trisomies only were present in 27 (28%) patients. Data on response and outcome of intensively treated patients were available for 92 cases. The median follow-up was 6.4 years (95% confidence interval [95% CI]: 2.9-9.0 years). The complete remission (CR) rate after induction therapy was 52% (48 patients); the early death rate was 10% (n=9). Notably, patients with trisomy 19 as the sole abnormality had a CR rate of 89%. Allogeneic hematopoietic stem cell transplantation (allo-HCT) was performed in 34 (35%) patients (CR, n=19; active disease, n=15). Five-year relapse-free and overall survival rates were 26% (95% CI: 16-43%) and 20% (95% CI: 13-31%), respectively. Overall survival rates were significantly higher in patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only (P=0.05). An Andersen-Gill model including allo-HCT as a time-dependent covariable on overall survival revealed that trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only was a favorable factor (hazard ratio [HR]=0.47; P=0.021); higher age at diagnosis had an adverse impact (10 years difference; HR=1.29; P=0.002), whereas allo-HCT did not have a beneficial impact (odds ratio=1.45; P=0.21). In our cohort, patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only had a high CR rate and better clinical outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Haematologica - 108(2023), 8 vom: 01. Aug., Seite 2059-2066 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 02.08.2023 Date Revised 02.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3324/haematol.2022.282127 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353216240 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353216240 | ||
| 003 | DE-627 | ||
| 005 | 20231226055509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2022.282127 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353216240 | ||
| 035 | |a (NLM)36815361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kayser, Sabine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2023 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We retrospectively studied 97 acute myeloid leukemia patients with trisomy 19 (median age at diagnosis 57 years; range, 17- 83 years) treated between 2001 and 2019 within two multicenter study groups. Trisomy 19 occurred alone in ten (10.5%) patients, with additional abnormalities being present in non-complex karyotypes in eight (8%) patients and in complex karyotypes in 79 (82%) patients. Altogether, karyotypes characterized by trisomies only were present in 27 (28%) patients. Data on response and outcome of intensively treated patients were available for 92 cases. The median follow-up was 6.4 years (95% confidence interval [95% CI]: 2.9-9.0 years). The complete remission (CR) rate after induction therapy was 52% (48 patients); the early death rate was 10% (n=9). Notably, patients with trisomy 19 as the sole abnormality had a CR rate of 89%. Allogeneic hematopoietic stem cell transplantation (allo-HCT) was performed in 34 (35%) patients (CR, n=19; active disease, n=15). Five-year relapse-free and overall survival rates were 26% (95% CI: 16-43%) and 20% (95% CI: 13-31%), respectively. Overall survival rates were significantly higher in patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only (P=0.05). An Andersen-Gill model including allo-HCT as a time-dependent covariable on overall survival revealed that trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only was a favorable factor (hazard ratio [HR]=0.47; P=0.021); higher age at diagnosis had an adverse impact (10 years difference; HR=1.29; P=0.002), whereas allo-HCT did not have a beneficial impact (odds ratio=1.45; P=0.21). In our cohort, patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only had a high CR rate and better clinical outcome | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Martínez-Cuadrón, David |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Veiga, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Hänel, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Tormo, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer-Eckart, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Botella, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Stölzel, Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Del Castillo, Teresa Bernal |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Medina, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Held, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Amigo, Maria-Luz |e verfasserin |4 aut | |
| 700 | 1 | |a Schliemann, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Colorado, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Manuel Barrios |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Stefan W |e verfasserin |4 aut | |
| 700 | 1 | |a Görner, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Jost, Edgar |e verfasserin |4 aut | |
| 700 | 1 | |a Steffen, Björn |e verfasserin |4 aut | |
| 700 | 1 | |a Zukunft, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Platzbecker, Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Anthony D |e verfasserin |4 aut | |
| 700 | 1 | |a Baldus, Claudia D |e verfasserin |4 aut | |
| 700 | 1 | |a Serve, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Thiede, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Bornhäuser, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Montesinos, Pau |e verfasserin |4 aut | |
| 700 | 1 | |a Röllig, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Schlenk, Richard F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 108(2023), 8 vom: 01. Aug., Seite 2059-2066 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:2059-2066 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2022.282127 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2023 |e 8 |b 01 |c 08 |h 2059-2066 | ||